GET DAILY SIGNALSHumacyte (HUMA): Can It Climb Back to the $1.75 Analyst Target?
Key Takeaways
- The central target of $1.75 is the arithmetic mean of five recently updated, verifiable analyst price targets, not an official published consensus.
- The five targets reviewed range widely, from $0.50 (Barclays) to $4.00 (H.C. Wainwright), reflecting deep disagreement about the company's path to profitability.
- With shares recently trading around $0.45 to $0.58, reaching $1.75 would require a gain of roughly 200% to 290% — a very large move.
- Supporting factors include the commercial launch of Symvess, positive Phase 3 dialysis data, and a planned supplemental regulatory filing.
- The biggest risks are heavy share dilution, a limited cash runway, tiny revenue, and Nasdaq minimum-bid listing pressure.
Reviewing the Latest Analyst Targets
A review of the most recent individual analyst price targets — those updated within the last several months — yields five verifiable figures: Barclays at $0.50 (Hold, Matt Miksic, October 2026), Benchmark at $1.00 (lowered from $2.00, Bruce Jackson, August 2026), TD Cowen at $1.25 (Buy, August 2026), BTIG at $2.00 (Buy, Ryan Zimmerman, July 2026), and H.C. Wainwright at $4.00 (Buy, Swayampakula Ramakanth, October 2026). The arithmetic mean of these five targets is $1.75, with a low-to-high range of $0.50 to $4.00. A sixth, older $25 target from D. Boral Capital has not been revised since spring 2026 and was treated as stale.
That dispersion is the key message: the mean is pulled upward by a couple of bullish forecasts, while the more cautious Barclays, Benchmark, and TD Cowen targets all sit below $1.75. The wide range reflects genuine uncertainty about whether HUMA can convert clinical progress into sustained commercial revenue before needing additional capital. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where HUMA Stands Today
HUMA shares have fallen roughly 66% over the past year, trading in a recent range of about $0.39 to $0.59, most recently near $0.45 to $0.58. At those levels, the $1.75 target implies upside of roughly 200% to 290% — by any measure, a very large move. The company generates minimal revenue (about $2.1 million over the trailing twelve months) against a net loss near $97 million, so the path to the target depends less on near-term earnings and more on regulatory milestones, commercial adoption, and how the market values the company's pipeline.
Factors That Could Drive the Stock Higher
- Symvess commercialization. The FDA-approved acellular tissue-engineered vessel (ATEV) for vascular trauma continues to add hospital accounts, and the FDA has extended its shelf life to 36 months.
- Dialysis opportunity. Positive Phase 3 V012 interim data for hemodialysis access, presented at Kidney Week 2026, supports a planned supplemental biologics license application (sBLA).
- Clear regulatory timeline. Management has targeted a November 2026 sBLA filing, a potential May 2027 PDUFA decision, and a dialysis launch around the end of the second quarter of 2027.
- Expanding indications. A first-in-human coronary bypass (CABG) study has been cleared by the FDA, broadening the long-term addressable market.
Risks That Could Hold It Back
- Dilution. Shares outstanding have risen about 46% year over year, and the company may need further equity raises to fund operations.
- Cash runway. With roughly $80 million in cash and a burn rate near $98 million annually, the runway is limited without new capital or a sharp revenue inflection.
- Listing risk. Trading below the $1 Nasdaq minimum-bid threshold raises the possibility of compliance pressure or a reverse split.
- Execution and competition. Slow commercial adoption, negative gross margins at low production volumes, and competition in vascular and dialysis markets all weigh on the valuation.
- Bearish positioning. Short interest represents roughly 11% of shares outstanding, reflecting meaningful skepticism.
Technical Picture
From a technical standpoint, the stock has been in a prolonged downtrend, trading well below its 200-day moving average near $0.79 and closer to its 50-day average near $0.49. The $1.00 level represents both a psychological round number and a likely resistance zone, while recent lows near $0.39–$0.40 form a nearby support area. A sustained move toward $1.75 would require the stock to first reclaim and hold above $1.00, a threshold it has struggled with for much of 2026. One thing that stands out after reviewing the charts is how consistently the stock has tested these levels without breaking through.
What to Watch Going Forward
Analyst price targets generally reflect a roughly 12-month research horizon, though individual timelines can differ. For HUMA, the most important near-term items are quarterly revenue and burn figures, confirmation of the sBLA filing, any PDUFA-related updates, and financing announcements. Investors should also watch analyst revisions, share-count changes, and whether the stock can regain Nasdaq compliance. None of these offers a guaranteed outcome. I’m watching this closely as the regulatory milestones approach.
Using Tickeron’s AI Daily Buy/Sell Signals
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals for volatile, low-priced names like this. The tool uses artificial intelligence to monitor thousands of stocks and generate Buy, Sell, or Hold signals based on technical behavior and changing market conditions. For a stock with this much uncertainty, it serves as a useful complement to fundamental work by highlighting potential shifts in momentum.
Final Assessment
Can HUMA reach $1.75? The level is not an official consensus but the average of five recently updated analyst targets spanning $0.50 to $4.00. It represents a very large move of roughly 200% to 290% from current levels. The bull case rests on Symvess adoption, dialysis regulatory progress, and a defined 2027 commercial roadmap, while the bear case emphasizes dilution, a constrained cash runway, sub-$1 listing risk, and minimal current revenue. The wide gap between the highest and lowest targets underscores that this is a binary, high-risk situation rather than a predictable climb. Investors should focus on the sBLA filing, cash position, share count, and commercial traction as the decisive signals ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HUMA in upward trend: price rose above 50-day moving average on November 10, 2026
HUMA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HUMA's RSI Oscillator exited the oversold zone, 34 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 58 cases where HUMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on HUMA as a result. In 74 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for HUMA just turned positive on October 21, 2026. Looking at past instances where HUMA's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Following a +31.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in 195 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
HUMA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HUMA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. HUMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.983) is normal, around the industry mean (3.498). P/E Ratio (-0.862) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.083) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement